Table 2 Adverse events related to treatment

From: Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial

 

# of patients with toxicity (%)

Side effects

All grades

Grade 3–4

Haematological

 Anaemia

7 (12.7%)

2 (3.6%)

 Leucopaenia

14 (25.4%)

0 (0%)

 Neutropenia

18 (32.7%)

3 (5.4%)

 Thrombocytopaenia

6 (10.9%)

0 (0%)

Nonhaematological

 Diarrhoea

28 (50.9%)

9 (16.4%)

 Fatigue

26 (47.3%)

7 (12.7%)

 Mucositis

21 (38.2%)

4 (7.3%)

 Nausea/vomiting

18 (32.7%)

3 (5.4%)

 Hypotension

9 (16.4%)

2 (3.6%)

 Fever

15 (27.3%)

0 (0%)

 Hypersensivity reaction

0 (0%)

0 (0%)

 Acne-like rash

39 (70.9%)

16 (29.1%)

Back to article page